Provider record
Fifty 410: What We Hold, and What We Have Asked
We hold 1 price record for Fifty 410. All are provider-reported rather than captured by us. Fifty 410 has answered none of the four disclosure questions we publish, so mo
We re-read Fifty 410’s own pages on November 20, 2026. Its lowest all-in figure for compounded tirzepatide was $149.50 a month (8-week program, $299 total (per 4 weeks; not available in some states)), or $199 month to month. Fifty 410 places =14 of 29 in our November 20, 2026 computed ranking, with 23 of the 40 points we measure for every program. FDA’s warning-letter index lists letter 721481 to Fifty 410, with no close-out letter listed when we checked on November 20, 2026; letters are shown for information and do not change scores. Sections below that show July 2026 records are kept as dated history.
Why this is a record and not a review
Our provider reviews run to about 2,500 words because we hold enough on those companies to write that much without padding. For Fifty 410 we do not. Writing the same length from one uncaptured figure would produce something that reads authoritative and tells you nothing.
So this page publishes exactly what we hold, marks every gap, and states what we have asked for. It becomes a review when there is something to review.
Every record we hold
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Fifty 410 | compounded | compounded injectable | — | — | — | — | not captured | third_party | — |
What we have asked, and what is unanswered
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
What is missing, and why it matters
The blank cells above are not omissions. Until Fifty 410 names its fulfilling pharmacy and registration class, a reader cannot check that pharmacy against a state board or against FDA warning letters, and cannot tell whether the FDA's proposed 503B bulks exclusion affects their supply. Until it publishes an all-in price at a maintenance dose, the figure above describes the start of treatment rather than the cost of it.
Both are things Fifty 410 can change in an afternoon, and we publish the answer either way — see the disclosure register.
Questions readers actually ask
Is Fifty 410 legitimate?
We have not assessed that. We hold price records and no answers to our disclosure questions, which is not enough to make a judgement in either direction.
How much does Fifty 410 cost?
We hold no obtainable figure, and it is provider-reported rather than captured by us. We do not know what it becomes at a maintenance dose.
Which pharmacy does Fifty 410 use?
They have not told us. No provider in our dataset has answered that question.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Henry Meds Tirzepatide ReviewProviders
- GLP-1 and Tirzepatide NewsNews
- GLP-1 and Tirzepatide JournalJournal
Related coverage
Tirzepatide Ranked. “Fifty 410: What We Hold, and What We Have Asked.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/fifty-410/
Quote the capture date beside a figure, not the date you read this page. Why.